Please login to the form below

Not currently logged in
Email:
Password:

T-DM1

This page shows the latest T-DM1 news and features for those working in and with pharma, biotech and healthcare.

‘Excitement’ around new data for Enhertu

‘Excitement’ around new data for Enhertu

emtansine (T-DM1). ... In the trial, nearly all patients treated with Enhertu were alive at one year (94.1%) compared to 85.9% of patients treated with T-DM1.

Latest news

  • FDA grants Enhertu Breakthrough Therapy Designation in breast cancer FDA grants Enhertu Breakthrough Therapy Designation in breast cancer

    The results of the phase 3 trial showed that Enhertu reduced the risk of disease progression or death by 72% vs trastuzumab emtansine (T-DM1). ... Nearly all patients treated with Enhertu were alive at one year (94.1%) compared to 85.9% of patients

  • Immunotherapy and future directions in oncology Immunotherapy and future directions in oncology

    Those dendritic cells can activate cytotoxic T-cells which, after replicating, track and eradicate cancer cells. ... Kadcyla (trastuzumab emtansine, Genentech of Roche) targets HER2 receptors present in breast cancer and delivers an anti-microtubule

  • EU backs Roche’s Kadcyla in breast cancer EU backs Roche’s Kadcyla in breast cancer

    Expectations are high for the Kadcyla, which is an antibody-drug conjugate (ADC) that combines the monoclonal antibody in Herceptin with ImmunoGen's DM1, a cytotoxic payload designed to boost its

  • Roche's Herceptin follow-up cleared in US Roche's Herceptin follow-up cleared in US

    FDA approval for Kadcyla (formerly T-DM1) in breast cancer. Roche won approval in the US late last week for Kadcyla, its much-anticipated follow-up to breast cancer blockbuster Herceptin. ... The FDA has given the go-ahead to Kadcyla, formerly known as

  • Product updates from Japan

    pylori", according to the partners. Chugai Pharmaceutical has filed for approval of trastuzumab emtansine (T-DM1) - originally developed by Roche/Genentech as a follow-up to their Herceptin (trastuzumab) blockbuster - for ... Chugai has commercialisation

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Havas Life Medicom

We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by...

Latest intelligence

5 ways we’re enhancing our services to support our clients in 2023
Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023....
ASH 2022: bad blood but big advances
Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...
Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....